Hudson Bay Capital Management
ELEV

Hudson Bay Capital Management’s Elevation Oncology ELEV Stock Holding History

Hudson Bay Capital Management’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,359,246
Closed -$815K – 975
2024
Q3 		$815K Sell
1,359,246
-1,038,522
-43% -$1.54M ﹤0.01% 696
2024
Q2 		$6.47M Buy
2,397,768
+886,867
+59% +$3.34M 0.03% 328
2024
Q1 		$7.75M Buy
1,510,901
+964,607
+177% +$3.13M 0.04% 218
2023
Q4 		$293K Hold
546,294
– – ﹤0.01% 569
2023
Q3 		$362K Hold
546,294
– – ﹤0.01% 613
2023
Q2 		$830K Buy
+546,294
New +$1.44M 0.01% 610
2021
Q3 		– Sell
-80,000
Closed -$1.09M – 1020
2021
Q2 		$1.09M Buy
+80,000
New +$989K 0.01% 717

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hudson Bay Capital Management's ELEV Position: Q4 2024 in Review

Hudson Bay Capital Management sold out of Elevation Oncology (ELEV) in Q4 2024, closing a stake of 1,359,246 shares — an estimated $815K sold.

Hudson Bay Capital Management first reported a position in ELEV in Q2 2021 and held it in 7 quarters. The position peaked at $7.75M in Q1 2024. 71 funds tracked by Wall St. Rank hold ELEV as of Q4 2024.

  • Hudson Bay Capital Management reported no remaining Elevation Oncology position as of Q4 2024 after selling out during the quarter.
  • Hudson Bay Capital Management sold 1,359,246 Elevation Oncology shares in Q4 2024, an estimated $815K.
  • Hudson Bay Capital Management first reported a position in Elevation Oncology in Q2 2021 and held it in 7 quarters.
  • Hudson Bay Capital Management's Elevation Oncology position peaked at $7.75M in Q1 2024.
  • 71 funds tracked by Wall St. Rank held Elevation Oncology as of Q4 2024.

Based on Hudson Bay Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.